A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
第2相
完了
NCT06454630
| 対象疾患 | Venous Thromboembolism |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Regeneron Pharmaceuticals |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 179 名 |
|---|
| 介入（薬剤） | REGN7508, Enoxaparin |
|---|
| 開始日 | 2024年6月27日 |
|---|
| 完了日 | 2024年11月19日 |
|---|
| 結果公開日 | 2026年3月2日 |
|---|
概要
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related diseases after unilateral total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)
Through day 12 · percentage of participants
| REGN7508 | 7.1 percentage of participants |
|---|
| Enoxaparin | 17.2 percentage of participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。